Company: OSRH
Filing Date: 2025-06-23
Form Type: 424B3
Source: 0001213900-25-056351
Chunk: 54

Company: OSR Holdings, Inc.
Filing Date: 2025-06-23
Form: 424B3
Chunk 54
---
 481,460 |   |
| Repayment of short-term borrowing                                                |     |                    |           - |   |     |      |   (336,378 | ) |
| Net cash provided by financing activities                                        |     |                    |     149,381 |   |     |      |    266,582 |   |
| Net change in cash and cash equivalents                                          |     |                    |   1,270,902 |   |     |      |     (5,562 | ) |
| Effects of changes in exchange rate on cash and cash equivalents                 |     |                    |     (16,749 | ) |     |      |    (22,210 | ) |
| Cash and cash equivalents at beginning of year                                   |     |                    |     341,543 |   |     |      |    540,207 |   |
| Cash and cash equivalents at end of year                                         |     | $                  |   1,595,697 |   |     | $    |    512,435 |   |
| Supplemental disclosures of cash flow information:                               |     |                    |             |   |     |      |            |   |
| Cash paid for interest                                                           |     | $                  |      16,991 |   |     | $    |     13,481 |   |
| Cash paid for income taxes (net of refunds received)                             |     |                    |         (35 | ) |     |      |      4,212 |   |

<div align='center'>The accompanying notes are an integral part of the condensed consolidated financial statements.

33

OSR HOLDINGS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

March 31, 2025 and 2024

(UNAUDITED)</div>

| (1) | Organization           
 and nature of business |

The condensed consolidated financial
statements of the Company and its subsidiaries (collectively, the “Group”) for the period ended March 31, 2025 were authorized
for issuance in accordance with a resolution of the directors meeting on May 7, 2025. The registered office is located at 37-36 Hoedong-gil,
Paju-si, Gyeongi-do, Republic of Korea.

The Company is a global life sciences
holding company based in South Korea and is actively engaging in drug development, dedicating to advance healthcare outcome and driving
social progress. Through open innovation and responsible investment,